Q06187 (BTK_HUMAN) Homo sapiens (Human)

Tyrosine-protein kinase BTK UniProtKBInterProSTRINGInteractive Modelling

659 aa; Sequence (Fasta) ; (Isoform 2; ) 12 identical sequences

Sequence Features

Add
 521Proton acceptor
 143Zinc
 154Zinc
 155Zinc
 165Zinc
 11L -> P (in XLA) VAR_006216
 12K -> R (in XLA) VAR_006217
 14S -> F (in XLA) VAR_006218
 19K -> E (in XLA) VAR_008291
 25F -> S (in XLA) VAR_006219
 27K -> R (in XLA) VAR_008292
 28R -> C (in XLA; no effect on phosphorylation of GTF2I) VAR_008293
 28R -> H (in XLA; moderate; dbSNP:rs128620185) VAR_006220 dbSNP
 28R -> P (in XLA) VAR_006221
 33T -> P (in XLA; severe; dbSNP:rs128620189) VAR_006222 dbSNP
 39Y -> S (in XLA) VAR_008960
 40Y -> C (in XLA; dbSNP:rs1555980875) VAR_008294 dbSNP
 40Y -> N (in XLA) VAR_008295
 61I -> N (in XLA) VAR_008296
 64V -> D (in XLA) VAR_008297
 64V -> F (in XLA) VAR_006223
 82R -> K (in dbSNP:rs56035945) VAR_041676 dbSNP
 103Q -> QSVFSSTR (in XLA) VAR_006224
 113V -> D (in XLA; dbSNP:rs128621190) VAR_006225 dbSNP
 115S -> F (in XLA) VAR_008298
 117T -> P (in XLA) VAR_008299
 127Q -> H (in XLA) VAR_008300
 154C -> S (in XLA) VAR_008301
 155C -> G (in XLA) VAR_008302
 155C -> R (in XLA) VAR_008303
 184T -> P (in XLA) VAR_008304
 190P -> K (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions) VAR_041677
 288R -> Q (in XLA; dbSNP:rs1555978277) VAR_008305 dbSNP
 288R -> W (in XLA; dbSNP:rs128621194) VAR_006227 dbSNP
 295L -> P (in XLA) VAR_006228
 302G -> E (in XLA) VAR_006230
 302G -> R (in XLA) VAR_008306
 302Missing (in XLA) VAR_006229
 307R -> G (in XLA; loss of activity; dbSNP:rs128621195) VAR_006231 dbSNP
 307R -> T (in XLA) VAR_008307
 308D -> E (in XLA) VAR_008308
 319V -> A (in XLA; moderate) VAR_008309
 334Y -> S (in XLA; dbSNP:rs128621196) VAR_006232 dbSNP
 358L -> F (in XLA) VAR_006233
 361Y -> C (in XLA; mild; dbSNP:rs28935478) VAR_006234 dbSNP
 362H -> Q (in XLA) VAR_006235
 364H -> P (in XLA) VAR_006236
 365N -> Y (in XLA) VAR_006237
 366S -> F (in XLA) VAR_008310
 369L -> F (in XLA) VAR_008311
 370I -> M (in XLA) VAR_006238
 372R -> G (in XLA) VAR_008312
 408L -> P (in XLA; moderate; dbSNP:rs128621198) VAR_006239 dbSNP
 414G -> R (in XLA) VAR_008313
 418Y -> H (in XLA; dbSNP:rs144079566) VAR_006240 dbSNP
 429I -> N (in XLA) VAR_006241
 430K -> E (in XLA; loss of phosphorylation of GTF2I; dbSNP:rs128620184) VAR_006242 dbSNP
 430K -> R (in XLA) VAR_008314
 445E -> D (in XLA) VAR_008315
 462G -> D (in XLA) VAR_008316
 462G -> V (in XLA) VAR_008317
 476Y -> D (in XLA) VAR_006243
 477M -> R (in XLA) VAR_006244
 481C -> S (found in patients with chronic lymphocytic leukemia; unknown pathological significance; results in resistance to ibrutinib therapy; results in a protein that is reversibly inhibited by ibrutinib; disrupts the covalent binding between the enzyme and ibrutinib; dbSNP:rs1057519825 and dbSNP:rs1057519826) VAR_074309 dbSNP
 502C -> F (in XLA) VAR_006245
 502C -> W (in XLA; dbSNP:rs41310709) VAR_006246 dbSNP
 506C -> R (in XLA; dbSNP:rs128621200) VAR_006247 dbSNP
 506C -> Y (in XLA) VAR_006248
 508A -> D (in XLA) VAR_008318
 509M -> I (in XLA) VAR_008319
 509M -> V (in XLA) VAR_006249
 512L -> P (in XLA) VAR_008961
 512L -> Q (in XLA) VAR_008962
 518L -> R (in XLA) VAR_008320
 520R -> Q (in XLA; severe; prevents activation due to absence of contact between the catalytic loop and the regulatory phosphorylated residue; dbSNP:rs128621202) VAR_006251 dbSNP
 521D -> G (in XLA) VAR_008321
 521D -> H (in XLA; severe) VAR_006252
 521D -> N (in XLA; severe) VAR_006253
 523A -> E (in XLA) VAR_008322
 525R -> G (in XLA) VAR_008323
 525R -> P (in XLA) VAR_006254
 525R -> Q (in XLA; severe; disturbs ATP-binding; dbSNP:rs128620183) VAR_006255 dbSNP
 526N -> K (in XLA; dbSNP:rs1569291237) VAR_006256 dbSNP
 535V -> F (in XLA) VAR_008324
 542L -> P (in XLA; growth hormone deficiency; dbSNP:rs128621203) VAR_006257 dbSNP
 544R -> G (in XLA) VAR_008963
 544R -> K (in XLA) VAR_006258
 559F -> S (in XLA) VAR_008325
 562R -> P (in XLA; dbSNP:rs104894770) VAR_006259 dbSNP
 562R -> W (in XLA; dbSNP:rs128621204) VAR_006260 dbSNP
 563W -> L (in XLA; dbSNP:rs1555977474) VAR_008326 dbSNP
 567E -> K (in XLA; severe) VAR_006261
 578S -> Y (in XLA) VAR_008964
 581W -> R (in XLA; dbSNP:rs128621205) VAR_006262 dbSNP
 582A -> V (in XLA) VAR_006263
 583F -> S (in XLA) VAR_008327
 587M -> L (in XLA; mild) VAR_006264
 589E -> D (in XLA) VAR_008328
 589E -> G (in XLA; moderate; interferes with substrate binding; dbSNP:rs128621206) VAR_006265 dbSNP
 589E -> K (in XLA) VAR_008965
 592S -> P (in XLA) VAR_006267
 594G -> E (in XLA; mild; interferes with substrate binding) VAR_006268
 594G -> R (in XLA; dbSNP:rs1555977339) VAR_006269 dbSNP
 598Y -> C (in XLA) VAR_006270
 607A -> D (in XLA; mild; dbSNP:rs128621208) VAR_006271 dbSNP
 613G -> D (in XLA; mild; interferes with substrate binding and/or domain interactions; dbSNP:rs128621209) VAR_006272 dbSNP
 619P -> A (in XLA) VAR_008330
 619P -> S (in XLA) VAR_006273
 619P -> T (in XLA) VAR_008331
 622A -> P (in XLA) VAR_008332
 626V -> G (in XLA) VAR_008333
 630M -> I VAR_006274
 630M -> K (in XLA; dbSNP:rs128621210) VAR_006275 dbSNP
 630M -> T (in XLA) VAR_008334
 633C -> Y (in XLA) VAR_006276
 641R -> C (in XLA) VAR_006277
 641R -> H (in XLA; severe) VAR_006278
 644F -> L (in XLA) VAR_008335
 644F -> S (in XLA) VAR_006279
 647L -> P (in XLA) VAR_006280
 652L -> P (in XLA; dbSNP:rs128622212) VAR_006281 dbSNP
 135-171Btk-type
 408-416ATP
 260-280Missing (in XLA; severe) VAR_006226
 5-133Pleckstrin homology domain
IPR001849PF00169
 141-167Zinc finger, Btk motif
IPR001562PF00779
 220-266SH3 domain
IPR001452PF00018
 281-362SH2 domain
IPR000980PF00017
 402-650Serine-threonine/tyrosine-protein kinase, catalytic domain
IPR001245PF07714

Sequence Alignments

Experimental structures

DescriptionOligo-stateLigandsStructureRange
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihyd… Heteromer
N42;5j87385-658
Assess
Ternary complex structure - BTK cIAP compound 15 Heteromer
Q13490;
ZN;TKY;6w8i393-657
Assess
Ternary complex structure - BTK cIAP compound 17 Heteromer
Q13490;
TL7;ZN;6w7o396-656
Assess
Crystal structure of human Btk SH2 domain bound to rF10 repebody Heteromer
6htf276-379
Assess
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT E41K IN COMPLEX WITH INS(1,3,4,5)P4homo-4-mer ZN;4IP;1bwn2-170
Assess
PH DOMAIN FROM BRUTON'S TYROSINE KINASE IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATEhomo-4-mer ZN;4IP;1b552-170
Assess
The structure of human BTK kinase domain in complex with a covalent inhibitorhomo-2-mer GYL;5xyz394-656
Assess
CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO …homo-2-mer 6MV;5jrs396-656
Assess
Crystal structure of Bruton's tyrosine kinase domainhomo-2-mer 1k2p397-654
Assess
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT R28Chomo-2-mer ZN;NA;1btk2-170
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGANDmonomer GJD;6di1389-659
Assess
BTK1 SOAKED WITH IBRUTINIB-Revmonomer 1E8;DMS;5p9i389-659
Assess
CRYSTAL STRUCTURE OF BTK with CNX 774monomer 7G8;5p9k389-659
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGANDmonomer GJG;6di0389-659
Assess
Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-…monomer 83P;EDO;PEG;5u9d389-659
Assess
BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTEREDmonomer X9M;7kxm389-659
Assess
BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxy…monomer KLM;EDO;6nfh389-659
Assess
BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059monomer 7GB;DMS;5p9m389-659
Assess
Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinibmonomer CL;MZJ;6omu389-659
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITORmonomer GJ7;DMS;6di5389-659
Assess
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R…monomer 4US;DMS;EDO;5bq0389-659
Assess
Bruton's tyrosine kinase (BTK) with GDC-0853monomer 9AJ;EDO;SO4;5vfi389-659
Assess
Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinasemonomer IMD;IPA;EDO;4L6;4z3v389-659
Assess
BTK1 SOAKED WITH COMPOUND 25monomer X9V;DMS;7kxp389-659
Assess
Discovery of affinity-based probes for Btk occupancy assaymonomer KHD;6n9p389-659
Assess
Crystal structure of ARQ 531 in complex with the kinase domain of BTKmonomer HRA;IMD;EDO;6e4f389-658
Assess
BTK1 SOAKED WITH COMPOUND 30monomer DMS;X9Y;7kxq390-659
Assess
Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragmentmonomer IMD;IPA;DMS;4RU;4zly389-658
Assess
Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnolinemonomer IMD;IPA;DMS;4RV;4zlz389-658
Assess
Crystal structure of BTK kinase domain complexed with 2-[4-(2-Diethylamino-ethoxy)-phenylamino]-6-(…monomer 04K;3pj2391-659
Assess
Crystal structure of BTK kinase domain complexed with 2-Methyl-5-[(E)-(3-phenyl-acryloyl)amino]-N-(…monomer 04L;3pj3391-659
Assess
Crystal structure of BTK kinase domain complexed with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-…monomer LHL;3pj1391-659
Assess
Crystal structure of BTK kinase domain complexed with (5-Amino-1-o-tolyl-1H-pyrazol-4-yl)-[3-(1-met…monomer 03C;3piz391-659
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITORmonomer GJJ;DMS;6di9392-659
Assess
BTK In Complex With Inhibitormonomer LTJ;6o8i391-658
Assess
Crystal structure of BTK kinase domain complexed with 2-Isopropyl-7-(4-methyl-piperazin-1-yl)-4-(5-…monomer 027;3pix391-658
Assess
BTK-inhibitor co-structuremonomer 5WH;5WE;5fbo392-659
Assess
Co-structure of BTK kinase domain with L-005085737 inhibitormonomer ULV;5WE;6x3n392-659
Assess
Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitormonomer 4C9;NA;EDO;SO4;CL;4yhf391-658
Assess
BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazo…monomer KLP;SO4;6nfi392-659
Assess
Crystal structure of BTK kinase domain complexed with R406monomer 585;3piy391-658
Assess
Co-crystal structure of BTK kinase domain with Zanubrutinibmonomer BA0;IMD;6j6m393-659
Assess
Bruton's tyrosine kinase in complex with compound 5monomer DMS;RQS;6vxq392-658
Assess
Bruton's tyrosine kinase in complex with compound 6monomer DMS;DTT;S5M;6w06393-659
Assess
The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-containi…monomer B43;3gen392-658
Assess
BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTEREDmonomer X9J;DMS;7kxl392-658
Assess
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggests a mechan…monomer 1N1;3k54392-658
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGANDmonomer GJA;6di3393-659
Assess
BTK1 COCRYSTALLIZED WITH IBRUTINIBmonomer 8E8;5p9j394-659
Assess
BTK1 IN COMPLEX WITH CC 292monomer 7G9;5p9l392-657
Assess
Co-structure of BTK kinase domain with L-005298385 inhibitormonomer UM4;EDO;BTB;6x3p394-659
Assess
BTK1 SOAKED WITH COMPOUND 26monomer X9P;DMS;7kxn394-659
Assess
Bruton's tyrosine kinase in complex with compound 1monomer S9A;DMS;6w07393-658
Assess
BTK IN COMPLEX WITH GDC-0834monomer 2VL;EDO;GOL;5p9f394-659
Assess
BTK in complex with LOU064, a potent and highly selective covalent inhibitormonomer NA;N6Z;6tfp393-658
Assess
BTK complex with compound 12monomer SO4;DXM;FPZ;GOL;6bkw393-657
Assess
Brutons tyrosine kinase in complex with compound 50.monomer L9S;EDO;6nzm395-659
Assess
Structure of BTK with RN486monomer 7G6;5p9g394-658
Assess
Co-structure of BTK kinase domain with L-005191930 inhibitormonomer ULY;5WE;6x3o395-659
Assess
BTK1 SOAKED WITH COMPOUND 24monomer X9S;DMS;7kxo395-659
Assess
Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-ca…monomer 2V1;4ot6394-658
Assess
Crystal structure of the human BTK kinase domainmonomer 3p08394-658
Assess
Bruton's tyrosine kinase (BTK) with pyridazinone compound 23monomer SO4;GOL;PG0;3YO;4rx5394-657
Assess
Bruton's tyrosine kinase (BTK) with pyridazinone compound 9monomer SO4;GOL;PG0;6XL;5kup394-657
Assess
Bruton's tyrosine kinase (BTK) with compound G-744monomer SO4;GOL;PG0;9B1;5vgo394-657
Assess
BTK kinase domain with inhibitor 1monomer 5WF;5WE;CL;5fbn395-658
Assess
BTK1 COCRYSTALLIZED WITH RN983monomer 7G7;5p9h395-658
Assess
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m…monomer GMQ;6hrp396-658
Assess
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymethy…monomer 3OV;DMS;4rfz396-658
Assess
BTK complex with compound 13monomer SO4;DY4;GOL;6bln395-657
Assess
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-…monomer GMW;6hrt396-658
Assess
Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-fl…monomer 73T;5t18396-658
Assess
Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazine-…monomer 481;DMS;4ot5396-658
Assess
Crystal structure of BTK kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl)-…monomer 2V2;DMS;4otq396-658
Assess
BTK Fluorocyclopropyl amide inhibitor, Compound 25monomer V1G;SO4;6xe4395-657
Assess
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815monomer SO4;BXM;6aub395-657
Assess
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625monomer GOL;SO4;BXJ;6aua394-656
Assess
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m…monomer 3OU;DMS;4rfy396-658
Assess
BTK complex with compound 7monomer SO4;DTJ;GOL;6bik395-657
Assess
BTK complex with compound 10monomer SO4;DVJ;6bke395-657
Assess
Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin-1…monomer 2V3;DMS;4otr396-658
Assess
Crystal structure of bruton's tyrosine kinase mutant V555R in complex with dasatinibmonomer 1N1;3oct394-656
Assess
Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiperaz…monomer BNB;6ep9396-658
Assess
Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-…monomer 3P0;4rg0396-658
Assess
BTK complex with compound 11monomer SO4;DVD;6bkh396-657
Assess
Crystal structure of bruton's tyrosine kinase in complex with inhibitor CGI1746monomer SO4;BME;746;3ocs395-656
Assess
BTK in complex with an inhibitormonomer L0Z;6s90395-656
Assess
Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834monomer SO4;2VL;4otf396-657
Assess
Crystal structure of Bruton agammaglobulinemia tyrosine kinase complexed with BMS-809959 aka 4-tert…monomer 2P5;4nwm396-657
Assess
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R…monomer 4UQ;5bpy396-657
Assess
Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2emonomer 9M3;5zz4395-655
Assess
The PH domain of Bruton's tyrosine kinase mutant R28Cmonomer MG;ZN;6tt22-169
Assess
Crystal Structure of 1-methylindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros…monomer MG;72V;ZN;6tse2-169
Assess
Crystal Structure of 5-chloroindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros…monomer 3IS;ZN;MG;6yyf2-169
Assess
Crystal Structure of 5-(trifluoromethoxy)indoline-2,3-dione covalently bound to the PH domain of Br…monomer Q1B;MG;ZN;6yyg2-169
Assess
Crystal Structure of 1,5-dimethylindoline-2,3-dione covalently bound to the PH domain of Bruton's t…monomer ZN;MG;6yyk2-169
Assess
The PH domain of Bruton's tyrosine kinase mutant R28Cmonomer NXT;MG;ZN;6tuh2-168
Assess
Crystal Structure of 5-bromoindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosi…monomer NYQ;ZN;MG;6tvn2-168
Assess
Crystal structure of PH domain of Bruton's tyrosine kinasemonomer ZN;4PT;2z0p2-168
Assess
Solution Structures of the SH2 domain of Bruton's Tyrosine Kinasemonomer 2ge9270-387
Assess
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, MINIMIZED AVERAGE STRUCTUREmonomer 1awx211-275
Assess
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, 42 STRUCTURESmonomer 1aww211-275
Assess
NMR Study of the SH3 Domain From Bruton's Tyrosine Kinase, 20 Structuresmonomer 1qly216-273
Assess

Homology models

Oligo-stateQMEANTemplateRangeSeq id (%)Ligands
monomer -1.20 4xi2.1.A214-657
98.21AU;
Assess
monomer -2.50 2h8h.1.A218-656
38.27
Assess
monomer -1.89 1opl.2.A275-657
39.82
Assess
monomer -2.81 1y57.1.A216-656
38.62
Assess

Homology models built on isoform sequence

IsoformOligo-stateLigandsQMEANTemplateRangeSeq id (%)
Isoform 2monomerAU;-1.224xi2.1.A248-691
98.21
Assess
Isoform 2monomer-2.184k11.1.A252-690
38.57
Assess
Isoform 2monomer-1.921opl.2.A309-691
39.82
Assess
Isoform 2monomer-2.781y57.1.A250-690
38.62
Assess